InxMed
Latest round
- Series C
Last raised
- Aug 2025
Total raised
- $118M
Investors
- 13
About InxMed
Established in 2017 and based in Shanghai, China, InxMed is a biotechnology company that focuses on the R&D of oncology drug resistance and tumor metastasis fields. The company established translational medicine and clinical teams in Shanghai, Beijing, and Nanjing in China, and hubs in the United States, Canada, and Australia. Moreover, the company has established cooperation with multinational pharmaceutical companies including Roche, Boehringer Ingelheim, and MSD. The company developed a new drug for ovarian cancer, IN10018, which was approved for Investigational New Drug (IND) application in April 2020, receives US FDA Fast Track Designation for ovarian cancer in August 2021, and receives the NMPA approval for a clinical trial of solid tumor in December 2021. The company's main business is the research, development, and production of anti-cancer drugs. The company's self-developed adhesive spot kinase (FAK) inhibitor IN10018 overcomes the drug resistance of KRAS G12C inhibitors and synergizes with KRAS G12C inhibitors in treating cancer, and can treat solid tumors, and ovarian cancers. The company also developed new drugs IN 30705 targeting cancer-associated fibroblast, and IN20130 targeting epigenetic regulators. InxMed generates revenue via researching, development, and production of anti-cancer drugs.
Who invested in InxMed
13 investors across 4 rounds
See all investors in InxMed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about InxMed
Who invested in InxMed?
InxMed has 13 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has InxMed raised?
InxMed has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did InxMed last raise money?
InxMed's most recent round on record is a Series C, in Aug 2025.
What does InxMed do?
Established in 2017 and based in Shanghai, China, InxMed is a biotechnology company that focuses on the R&D of oncology drug resistance and tumor metastasis fields.
Where is InxMed headquartered?
InxMed is headquartered in Shanghai, China.
Which VCs invest in companies like InxMed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at InxMed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like InxMed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.